The role of combining immunotherapy with primary (Chemo)radiotherapy in curative treatment settings of the head and neck cancer
© 2021 John Wiley & Sons Australia, Ltd..
The introduction of immunotherapy into the radical management of head and neck cancer (HNC) is a fast moving phenomenon, which is constantly developing. Although now established in the management of recurrent and metastatic disease in HNC, its use in radical treatment is being investigated in a whole spectrum of clinical trials looking at which immune altering agents give the best results, which can be added safely to radiotherapy, chemotherapy, and chemoradiotherapy for greatest efficiency and when the most appropriate time to add these agents is in the neoadjuvant, concurrent on adjuvant settings. These multiple questions produce a complex matrix for HNC investigators and this article brings together the existing evidence and contemporary trials going on with immunotherapy in HNC, giving an up to date snapshot of present investigations and near future directions for further research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Asia-Pacific journal of clinical oncology - 18(2022), 2 vom: 01. Apr., Seite e3-e10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dua, Divyanshu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.04.2022 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajco.13583 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327092831 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327092831 | ||
| 003 | DE-627 | ||
| 005 | 20231225200019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajco.13583 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327092831 | ||
| 035 | |a (NLM)34162017 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dua, Divyanshu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of combining immunotherapy with primary (Chemo)radiotherapy in curative treatment settings of the head and neck cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2022 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a The introduction of immunotherapy into the radical management of head and neck cancer (HNC) is a fast moving phenomenon, which is constantly developing. Although now established in the management of recurrent and metastatic disease in HNC, its use in radical treatment is being investigated in a whole spectrum of clinical trials looking at which immune altering agents give the best results, which can be added safely to radiotherapy, chemotherapy, and chemoradiotherapy for greatest efficiency and when the most appropriate time to add these agents is in the neoadjuvant, concurrent on adjuvant settings. These multiple questions produce a complex matrix for HNC investigators and this article brings together the existing evidence and contemporary trials going on with immunotherapy in HNC, giving an up to date snapshot of present investigations and near future directions for further research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Kelly, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Kovarik, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Iqbal, Muhammad Shahid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Asia-Pacific journal of clinical oncology |d 2010 |g 18(2022), 2 vom: 01. Apr., Seite e3-e10 |w (DE-627)NLM197405231 |x 1743-7563 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:2 |g day:01 |g month:04 |g pages:e3-e10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajco.13583 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 2 |b 01 |c 04 |h e3-e10 | ||